A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer
The THR cell-of-origin signature introduces a novel dimension to breast cancer biology, potentially serving as a robust foundation for integrating additional prognostic biomarkers. These signatures offer utility as a prognostic index for stratifying existing breast cancer subtypes and for de novo classification of breast cancer cases. Moreover, THR signatures may also hold promise in predicting hormone treatment responses targeting AR and/or VDR.
Authors
- Tan A. Ince (ORCID: https://orcid.org/0000-0003-0315-6425)
- Mohamed Omar (ORCID: https://orcid.org/0000-0002-8068-1920)
- Rulla M. Tamimi (ORCID: https://orcid.org/0000-0003-2306-8668)
- Harikrishna Nakshatri (ORCID: https://orcid.org/0000-0001-8876-0052)
- Cihat Erdoğan (ORCID: https://orcid.org/0000-0001-5495-7754)
- Luigi Marchionni (ORCID: https://orcid.org/0000-0002-7336-8071)
- J. Chuck Harrell
Institutions
- NewYork–Presbyterian Brooklyn Methodist Hospital (US)
- Virginia Commonwealth University (US)
- Cornell University (US)
- Dana-Farber Cancer Institute (US)
- Weill Cornell Medicine (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1186/s13058-024-01876-9
- Citations
- 4
- Primary Topic
- Gene expression and cancer classification
- Type
- article
- Field-Weighted Citation Impact
- 0.94